UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...
Investor's Business Daily on MSN
Coal Stocks Pare Gains Amid The Rare Earths Craze
Stocks for some coal companies are up 200% this year, as investors hope they'll reinvent themselves as rare earth miners.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback